Therapeutic potential of an anti-diabetic drug, metformin: Alteration of miRNA expression in prostate cancer cells

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 2, 2013, Pages 765-768

  Avci, Cigir Biray ^a   Harman, Ece ^b   Dodurga, Yavuz ^c   Susluer, Sunde Yilmaz ^a   Gunduz, Cumhur ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b IZMIR KATIP CELEBI UNIVERSITY   (Turkey)

^c PAMUKKALE UNIVERSITY   (Turkey)

Author keywords

Metformin; MiRNA profiling.; MiRNAs; Prostate cancer

Indexed keywords

ANTIDIABETIC AGENT; ANTINEOPLASTIC AGENT; METFORMIN; MICRORNA; MIRN100 MICRORNA, HUMAN; MIRN106 MICRORNA, HUMAN; MIRN146 MICRORNA, HUMAN; MIRN193 MICRORNA, HUMAN; MIRN425 MICRORNA, HUMAN;

ARTICLE; BIOSYNTHESIS; CELL PROLIFERATION; CELL SURVIVAL; DOWN REGULATION; DRUG EFFECT; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; PROSTATE TUMOR; TUMOR CELL LINE; UPREGULATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOWN-REGULATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MICRORNAS; PROSTATIC NEOPLASMS; UP-REGULATION;

EID: 84877673227     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.2.765     Document Type: Article

References (22)

1. Baranwal S, Alahari SK (2010) miRNA control of tumor cell invasion and metastasis. Int J Cancer, 126, 1283-90.
2. Benjamini, Y, Hochberg Y (1995). Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc B, 57, 289-300.
3. Ben SI, Laurent K, Loubat A, et al (2008). The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene, 27, 3576-86.
4. Decensi A, Puntoni M, Goodwin P, et al (2010). Metformin and cancer risk in diabetic patients, a systematic review and meta-analysis. Cancer Prev Res, 3, 1451-61.
5. De Hoon MJL, Imoto S, Nolan JN, Miyano S (2004). Open source clustering software. Bioinformatics, 20, 1453-4.
6. Gotlieb WH, Saumet J, Beauchamp MC, et al (2008). In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol Oncol, 110, 246-50.
7. Hernes E, Kyrdalen A, Kvåle R, et al (2010). Initial management of prostate cancer, first year experience with the Norwegian National Prostate Cancer Registry. BJU Int, 105, 805-11.
8. Iorio MV, Croce CM (2009). MicroRNAs in cancer, small molecules with a huge impact. J Clin Oncol, 27, 5848-56.
9. Isakovic A, Harhaji L, Stevanovic D, et al (2007). Dual antiglioma action of metformin, cell cycle arrest and mitochondria-dependent apoptosis. Cell Mol Life Sci, 64, 1290-302.
10. Jemal A, Siegel R, Ward E, et al (2009). Cancer statistics, 2009. CA Cancer J Clin, 59, 225-49.
11. Kong DJ, Li YW, Wang ZW, Banerjee S, et al (2009). miR- 200 regulates PDGF-D-mediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells. Stem Cells, 27, 1712-21.
12. Landman GW, Kleefstra N, van Hateren KJ, et al (2010). Metformin associated with lower cancer mortality in type 2 diabetes, ZODIAC-16. Diabetes Care, 33, 322-6.
13. Libby G, Donnelly LA, Donnan PT, et al (2009). New users of metformin are at low risk of incident cancer, a cohort study among people with type 2 diabetes. Diabetes Care, 32, 1620-5.
14. Lin SL, Chiang A, Chang D, Ying SY (2008). Loss of mir-146a function in hormone-refractory prostate cancer. RNA, 14, 417-24.
15. Mattie MD, Benz CC, Bowers J, et al (2006). Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer, 5, 24
16. Murtola TJ, Tammela TL, Lahtela J, et al (2008). Antidiabetic medication and prostate cancer risk, a population-based case-control study. Am J Epidemiol, 168, 925-31
17. Porkka KP, Pfeiffer MJ, Waltering KK et al (2007). MicroRNA expression profiling in prostate cancer. Cancer Res, 67, 6130-5.
18. Schaefer A, Jung M, Kristiansen G, et al (2009). MicroRNAs and cancer, current state and future perspectives in urologic oncology. Urol Oncol, 28, 4-13.
19. Sharov AA, Dudekula DB, Ko MSH (2005). Principal component and significance analysis of microarrays with NIA Array Analysis tool. Bioinformatics, 21, 2548-9.
20. Shi XB, Xue LR, Yang J, et al (2007). An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells. Proc Natl Acad Sci USA, 104, 19983-88.
21. Vrba L, Jensen TJ, Garbe JC, et al (2010). Role for DNA methylation in the regulation of miR-200c and miR-141 expression in normal and cancer cells. PLoS One, 5, 8697.
22. Wright JL, Stanford JL (2009). Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Causes Control, 20,1617-22.